Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit from investors who purchased securities during a specified period, alleging misleading statements regarding the viability of its drug development programs [1][4]. Company Overview - Intellia is a genome editing company focused on developing curative therapeutics, with a notable project being NTLA-3001 for treating alpha-1 antitrypsin deficiency-associated lung disease [3]. Allegations in the Lawsuit - The lawsuit claims that Intellia's management made false or misleading statements about the viability and development of NTLA-3001, including: - Misrepresentation of reliable information regarding NTLA-3001's development and marketing potential [4]. - Overly optimistic timelines for dosing and future studies that did not align with reality [4]. - Lack of capability to timely dose patients or maintain research and development for NTLA-3001 due to the challenges of viral-based editing methods [4]. - Concerns about the cost and inefficiency of viral-based editing drugs, even if NTLA-3001 was successful [4]. Impact of Company Reorganization - On January 9, 2025, Intellia announced a reorganization, prioritizing resources towards NTLA-2002 and nex-z, leading to the discontinuation of NTLA-3001. This announcement resulted in a stock price drop of over 15% [5].

NEW YORK, April 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/intellia-therapeutics-inc-loss-submission-form/?id=141927&from=4CLASS PERIOD ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Intellia Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Intellia securities is from July 30, 2024, to January 8, 2025, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Background - The lawsuit alleges that Intellia provided misleading information regarding its Phase 1/2 study for NTLA-3001, which is aimed at treating alpha-1 antitrypsin deficiency-associated lung disease [4]. - Defendants reportedly failed to disclose that demand for viral-based editing was declining as non-viral methods gained preference due to cost-effectiveness and efficiency [4]. - The lawsuit claims that when the true information became public, investors suffered damages [4].

NEW YORK, April 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Intellia and certain of i ...

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its NTLA-3001 program for treating alpha-1 antitrypsin deficiency-associated lung disease, which has been discontinued following a company reorganization [1][2]. Group 1: Company Developments - The class period for the lawsuit is from July 30, 2024, to January 8, 2025, during which Intellia allegedly provided investors with optimistic timelines for the NTLA-3001 study [2]. - On January 9, 2025, Intellia announced a halt to all NTLA-3001 research and a 27% workforce reduction, indicating a shift in focus to other pharmaceutical developments [2]. - Following the announcement, Intellia's stock price dropped from $12.02 per share on January 8, 2025, to $10.20 per share on January 10, 2025 [2]. Group 2: Legal Proceedings - Shareholders who purchased shares during the class period are encouraged to register for the class action, with a deadline of April 14, 2025, to seek lead plaintiff status [3]. - Participants in the class action will be enrolled in a portfolio monitoring system to receive updates on the case [3]. - The Gross Law Firm, which is leading the class action, aims to protect investors' rights and recover losses incurred due to misleading statements by the company [4].

Core Points - Rosen Law Firm is reminding investors who purchased Intellia Therapeutics, Inc. securities between July 30, 2024, and January 8, 2025, of the April 14, 2025, lead plaintiff deadline [1] - Investors may be entitled to compensation through a contingency fee arrangement without any out-of-pocket costs [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the firm [3][6] Company Details - The lawsuit claims that during the Class Period, Intellia provided misleading information regarding its Phase 1/2 study for NTLA-3001, which is aimed at treating alpha-1 antitrypsin deficiency-associated lung disease [5] - Defendants allegedly failed to disclose that demand for viral-based editing was declining as non-viral methods gained preference due to cost-effectiveness and efficiency, making NTLA-3001 an inefficient program for Intellia [5] Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience [4] - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Intellia Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's clinical study and subsequent strategic decisions [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Intellia between July 30, 2024, and January 8, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Intellia, with a deadline of April 14, 2025, for investors to seek the role of lead plaintiff [2][7]. Group 2: Company Developments - Intellia announced a strategic shift on January 9, 2025, focusing on drug candidates NTLA-2002 and nex-z, while discontinuing the development of NTLA-3001, leading to a workforce reduction of approximately 27% [5]. - The company expects to incur charges of around $8 million in the first quarter of 2025 due to this restructuring [5]. Group 3: Market Reaction - Following the announcement of the strategic changes, Intellia's stock price fell by $1.82 per share, or 15.14%, closing at $10.20 per share on January 10, 2025 [6].

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its drug development, particularly for NTLA-3001, which has led to significant stock price declines [4][5]. Group 1: Company Overview - Intellia Therapeutics is a genome editing company focused on developing curative therapeutics [3]. - The company received authorization from the UK's Medicine and Healthcare products Regulatory Agency for a Phase 1/2 study of NTLA-3001 targeting alpha-1 antitrypsin deficiency-associated lung disease on July 30, 2024 [3]. Group 2: Allegations in the Lawsuit - The lawsuit claims that Intellia's management made false or misleading statements about the viability of NTLA-3001's development and marketing potential [4]. - It is alleged that the company provided overly optimistic timelines for drug dosing and future studies, which did not align with reality [4]. - The complaint states that Intellia was not adequately prepared to dose patients with NTLA-3001 or maintain its research and development efforts due to the challenges of viral-based editing methods [4]. - The lawsuit also highlights that even if NTLA-3001 was successful, the use of viral-based editing drugs is costly and inefficient [4]. Group 3: Impact on Stock Price - Following the announcement of a company reorganization on January 9, 2025, which included the discontinuation of NTLA-3001, Intellia's stock price fell by more than 15% [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Intellia Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Intellia securities between July 30, 2024, and January 8, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - The deadline to move the Court to serve as lead plaintiff is April 14, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360 [3]. Group 3: Case Background - The lawsuit alleges that Intellia provided misleading information regarding its Phase 1/2 study for NTLA-3001, particularly about the timeline for dosing the first patient [4]. - It is claimed that Intellia failed to disclose the declining demand for viral-based editing methods, which could render NTLA-3001 an inefficient program [4].

Core Viewpoint - Intellia Therapeutics has initiated the first patient dosing in the MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z), targeting hereditary ATTR amyloidosis with polyneuropathy, which could potentially redefine treatment paradigms for this debilitating disease [1][2][3]. Group 1: Clinical Trial Details - The MAGNITUDE-2 study is a pivotal Phase 3, randomized, double-blind, placebo-controlled trial involving approximately 50 patients with ATTRv-PN [4]. - The primary endpoints include a modified neuropathy impairment score and changes in serum TTR levels, with patients randomized to receive either a single 55 mg infusion of nex-z or a placebo [4]. - Intellia aims to submit a biologics licensing application (BLA) for ATTRv-PN by 2028, following the presentation of longer-term data from Phase 1 studies later this year [3][4]. Group 2: Product Information - Nexiguran ziclumeran (nex-z) is based on CRISPR/Cas9 technology and is designed to inactivate the TTR gene responsible for producing the mutated transthyretin protein [5]. - Interim Phase 1 data indicated that a single dose of nex-z resulted in consistent, deep, and long-lasting reductions in TTR levels [5]. - Nex-z has received Regenerative Medicine Advanced Therapy designations from the U.S. FDA for both polyneuropathy and cardiomyopathy, as well as Orphan Drug Designation from both the U.S. FDA and European Commission [5]. Group 3: Disease Background - Transthyretin amyloidosis (ATTR) is a rare, progressive, and fatal disease, with hereditary ATTR (ATTRv) caused by mutations in the TTR gene leading to the production of abnormal TTR proteins [6]. - Approximately 50,000 individuals globally are affected by ATTRv amyloidosis, with no known cure and limited treatment options available to slow the progression of the disease [6].